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ABSTRACT HIV-1 Nef binds to the cytoplasmic region of HLA-A and HLA-B and downregulates these molecules from the sur-
face of virus-infected cells, thus evading immune detection by CD8 T cells. Polymorphic residues within the HLA cytoplasmic
region may affect Nef’s downregulation activity. However, the effects of HLA polymorphisms on recognition by primary Nef
isolates remain elusive, as do the specific Nef regions responsible for downregulation of HLA-A versus HLA-B. Here, we exam-
ined 46 Nef clones isolated from chronically HIV-1 subtype B-infected subjects for their ability to downregulate various HLA-A,
HLA-B, and HLA-C molecules on the surface of virus-infected cells. Overall, HLA-B exhibited greater resistance to Nef-mediated
downregulation than HLA-A, regardless of the cell type examined. As expected, no Nef clone downregulated HLA-C. Impor-
tantly, the differential abilities of patient-derived Nef clones to downregulate HLA-A and HLA-B correlated inversely with the
sensitivities of HIV-infected target cells to recognition by effector cells expressing an HIV-1 Gag-specific T cell receptor. Nef
codon function analysis implicated amino acid variation at position 202 (Nef-202) in differentially affecting the ability to down-
regulate HLA-A and HLA-B, an observation that was subsequently confirmed by experiments using Nef mutants constructed by
site-directed mutagenesis. The in silico and mutagenesis analyses further suggested that Nef-202 may interact with the
C-terminal Cys-Lys-Val residues of HLA-A, which are absent in HLA-B. Taken together, the results show that natural polymor-
phisms within Nef modulate its interaction with natural polymorphisms in the HLA cytoplasmic tails, thereby affecting the effi-
ciency of HLA downregulation and consequent recognition by HIV-specific T cells. These results thus extend our understanding
of this complex pathway of retroviral immune evasion.
IMPORTANCE Recognition of genetically diverse pathogens by the adaptive immune system represents a primary strategy for
host defense; however, pathogens such as HIV-1 can evade these responses to achieve persistent infection. The HIV-1 nef gene
and the HLA class I locus rank among the most diverse genes of virus and host, respectively. The HIV-1 Nef protein interacts
with the cytoplasmic region of HLA-A and HLA-B and downregulates these molecules to evade cellular immunity. By combining
molecular, genetic, and in silico analyses, we demonstrate that patient-derived Nef clones downregulate HLA-A more effectively
than HLA-B molecules. This in turn modulates the ability of HIV-specific T cells to recognize HIV-infected cells. We also identify
a naturally polymorphic site at Nef codon 202 and HLA cytoplasmic motifs (GG314,315 and CKV339 –341) that contribute to differ-
ential HLA downregulation by Nef. Our results highlight new interactions between HIV-1 and the human immune system that
may contribute to pathogenesis.
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The HLA class I (HLA-I) gene region, comprising the HLA-A,HLA-B, and HLA-C loci, ranks among the most polymorphic
regions in the human genome, with 2,735 HLA-A, 3,455 HLA-B,
and 2,259 HLA-C alleles identified to date (International ImMu-
noGeneTics project [IMGT] HLA database; http://www.ebi-
.ac.uk/ipd/imgt/hla/) (see reviews in references 1 and 2). HLA-I
polymorphism is mainly concentrated within exons 2 and 3 (1),
which primarily form the antigenic peptide-binding groove of the
HLA-I complex (3) and play an important role in restricting
CD8 T lymphocyte specificity. Other exons also exhibit poly-
morphism, albeit to a lesser extent. For example, HLA-A, HLA-B,
and HLA-C alleles can be classified into 5, 2, and 7 polymorphic
types, respectively, based on sequence variations within their cy-
toplasmic domains (encoded by exons 5 to 7 for HLA-B or 5
through 8 for HLA-A and HLA-C). Polymorphism in the cyto-
plasmic domain also influences receptor expression: for example,
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a unique amino acid conserved in all HLA-C allotypes (Ile at
codon 337 [Ile-337], rather than Thr-337 as in HLA-A and
HLA-B) yields lower cell surface expression of HLA-C than of
HLA-A and HLA-B (4). However, the implications of HLA cyto-
plasmic polymorphisms formodulation of antiviral immunity re-
main incompletely understood.
HLA-I-restricted CD8 cytotoxic T lymphocyte (CTL) re-
sponses are important for controlling a wide range of viral infec-
tions (5, 6), including HIV-1 (7, 8), human T-cell leukemia virus
type 1 (HTLV-1) (9), cytomegalovirus (10), and herpes simplex
virus (11) infections. In turn, viruses have evolved various mech-
anisms to evade HLA-I-restricted antiviral immunity, such as in-
hibiting intracellular antigen-processing pathways and down-
regulating HLA-I molecules from the infected cell surface (see
reviews in references 12 to 14). In HIV-1, the 27- to 35-kDa acces-
sory protein Nef downregulates HLA-A and HLA-B molecules
from the surface of HIV-1-infected cells (15, 16). Nef does not
downregulate HLA-C molecules due to the presence of unique
residues at codons 320 and 327 in their cytoplasmic regions (17).
As such, the antiviral activities of HLA-A and HLA-B-restricted
CTLs are substantially reduced by Nef expression (18–20),
whereas the antiviral activities of HLA-C-restricted CTLs are un-
affected by Nef (21). Maintenance of HLA-C expression allows
virus-infected cells to escape recognition by the innate immune
system, as downregulation of all HLA-I molecules would render
HIV-infected cells susceptible to recognition by natural killer cells
(22). Importantly, it was recently demonstrated that chimeric
HLA-A02 molecules expressing various HLA-A and HLA-B cyto-
plasmic tails are differentially susceptible to Nef-mediated down-
regulation and that this in turn has implications for infected-cell
recognition by HLA-A02-restricted CTLs (23). However, all prior
studies focused on a limited number of prototypic laboratory-
adapted HIV-1 strains (22, 23). It is thus unclear whether highly
diverse naturally occurring (patient-derived) Nef sequences also
display differential abilities to downregulate HLA-A and HLA-B,
and if so, which Nef residue(s) modulate these interactions.
Nef ranks among the most diverse HIV-1 proteins (24, 25).
Primary Nef clones isolated from patients at various infection
stages and/orwith different disease phenotypes exhibit substantial
functional heterogeneity (26–31), including wide-ranging HLA-I
downregulation capacities (26, 28–30, 32–35). However, previous
studies investigated a variety of HLA-I allotypes using different
target cells and antibodies; as such, the possibility that these dif-
ferences were influenced in part by the experimental conditions
cannot be conclusively ruled out. In this study, we assessed 46
subtype B Nef clones isolated from the same number of chroni-
callyHIV-1-infected patients for their ability to downregulate var-
ious HLA-A, HLA-B, and HLA-C allotypes. Individual primary
Nef clones exhibited differential abilities to downregulate HLA-I
allotypes, withHLA-Bmolecules exhibiting decreased susceptibil-
ity to Nef-mediated downregulation compared to the susceptibil-
ity of HLA-A (whereas HLA-C was resistant to Nef’s effects). Dif-
ferential Nef-mediated downregulation of HLA-A versus HLA-B
molecules in turnmodulated the ability of HIV-specific effector T
cells to recognize HIV-infected target cells. By combining statisti-
cal analysis, site-specific mutagenesis, and structural interpreta-
tion, we identified natural polymorphisms within Nef and HLA
cytoplasmic sequences that contribute to Nef’s differential abili-
ties to downregulate HLA-A and HLA-B molecules.
RESULTS
Differential downregulation of HLA-A, HLA-B, and HLA-C by
HIV-1 laboratory strains. To investigate differential downregu-
lation of various HLA-A, HLA-B, and HLA-C allotypes by HIV-1
Nef, we stably transfected HLA class I-deficient 721.221 cells with
HLA-A*02:01 (A02), HLA-A*24:02 (A24), HLA-A*33:01 (A33),
HLA-B*35:01 (B35), HLA-B*57:01 (B57), or HLA-C*04:01
(C04). The cytoplasmic tails of HLA-B molecules are 3 amino
acids shorter than those of HLA-A and HLA-C molecules
(Fig. 1A). Moreover, HLA-A allotypes harbor aspartic acid and
arginine at codons 314 and 315, respectively (DR314,315), whereas
HLA-B and HLA-C allotypes harbor dual glycines (GG314,315).
There are additional amino acid differences between individual
allotypes within the cytoplasmic regions (Fig. 1A). The cell surface
expression of HLA-I molecules on 721.221 cells was stable and
substantial (Fig. 1B, top row). Specifically, the levels of surface
expression of the three HLA-A (A02, A24, and A33) and two
HLA-B (B35 and B57) allotypes were comparable when cells were
stained with the pan-HLA-specific monoclonal antibody (MAb)
w6/32, whereas the surface expression of the HLA-C allotype
(C04) was lower, as expected. No changes in cell surface HLA-I
expression were observed in cells infected with the HIV-1 refer-
ence strain NL43 engineered to lack Nef (NL43-Nef) (Fig. 1B,
middle row). In contrast, when cells were infected with vesicular
stomatitis virus envelope glycoprotein (VSV-g)-pseudotyped
HIV-1 NL43 expressing the Nef gene from the prototypic labora-
tory strain SF2 (NL43-NefSF2), all HLA-A and HLA-B allotypes
were downregulated from the cell surface, whereas the HLA-C
allotype was unaffected (Fig. 1B, bottom row). As described in
Materials andMethods,HLA-I downregulation activitywas quan-
tified using a scale from 0% (denoting no HLA-I downregulation
activity in virus-infected cells) to 100% (denoting complete
downregulation activity). The greater the downregulation activity
value, the lower the residual cell surface expression of HLA-I.
NefSF2’s ability to downregulate individual HLA-A and HLA-B
molecules varied to some extent; the downregulation values
(mean standard deviation [SD]), by allotype, were 71.4% 
3.1% for A02, 61.2%  3.7% for A24, 57.4%  2.4% for A33,
50.1%  2.4% for B35, and 52.4%  3.1% for B57 (Fig. 1C).
Importantly, NefSF2’s ability to downregulate HLA-A alleles con-
sistently exceeded that of HLA-B (Mann-Whitney test, P 
0.001). Two other laboratory HIV-1 Nef strains, NefNL43 and
NefJRFL, were also evaluated for their ability to downregulate A24
and B35 (see Fig. S1 in the supplemental material). In both cases,
their ability to downregulate HLA-A exceeded their ability to
downregulate HLA-B (Mann-Whitney, P  0.001), and neither
downregulated C04.
Differential downregulation of HLA-A, HLA-B, and HLA-C
by natural Nef sequences. We next assessed whether patient-
derived Nef sequences differed in their ability to downregulate
HLA-A, HLA-B, and HLA-C allotypes. For these experiments, we
used 721.221 cells stably expressing A24, B35, and C04 as allotype
representatives. A24 and B35 were chosen because they exhibited
levels of susceptibility to Nef-mediated downregulation similar to
the median values of the HLA-A and HLA-B allotypes tested
(Fig. 1C), while C04 was chosen because the 721.221 cells express-
ing this allele exhibited themost stable cell surface HLA-C expres-
sion among our panel of 721.221 cells engineered to express var-
ious HLA-C allotypes. Representative HLA-I downregulation
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data, derived from cells infected withHIV-1NL43-derived strains
encoding Nef clonal sequences from three chronic progressors
(subjects CP66, CP84, and CP90) are shown in Fig. 2A. The three
patient-derived Nef clones varied in their ability to downregulate
A24 and B35, but none downregulated C04. For example, CP66-
Nef’s B35 downregulation activity was 23%, which was approxi-
mately half of that of NefSF2 (49%, Fig. 1B). In contrast, CP84-
Nef’s A24 and B35 downregulation activities, 66% and 56%,
respectively, were comparable to those ofNefSF2. CP90-Nef down-
regulated A24 and B35 by equivalent, relatively lower levels (38%
and 41%, respectively).
To quantify the ability of naturally occurring Nef sequences to
downregulate A24 and B35, we expanded this analysis to 46
patient-derived Nef clones. All 46 Nef clones displayed greater
ability to downregulate A24 (median activity of 60.8% [interquar-
tile range {IQR}, 54.2 to 65.5]) than B35 (median activity, 49.3%
[IQR, 41.0 to 55.5]) (Fig. 2B), a difference that was highly statis-
tically significant (Mann-Whitney, P  0.001). No clone down-
regulated C04. To quantify each virus’ ability to differentially
downregulate A24 versus B35, we expressed the downregulation
values as pairwise ratios. Overall, the median ratio of A24/B35
downregulation activities of patient-derived Nef clones was 1.25
A02
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FIG 1 Downregulation of HLA-A, HLA-B, and HLA-C by laboratory Nef strain SF2. (A) Amino acid sequences of the cytoplasmic tails of HLA-A*02:01 (A02),
HLA-A*24:02 (A24), HLA-A*33:01 (A33), HLA-B*35:01 (B35), HLA-B*57:01 (B57), and HLA-C*04:01 (C04) proteins. Dots denote amino acid residues
identical to A02, and dashes denote the absence of amino acids at those positions. (B) HLA-I-deficient 721.221 cells stably transfected with the indicated HLA-I
moleculewere infectedwith recombinantHIV-1 lackingNef (Nef) or carryingNefSF2.Uninfected cultureswere also used as controls. The cells were stainedwith
an antibody toHLA class I (clonew6/32), followed by intracellular stainingwith an antibody to p24Gag. Nef-mediatedHLAdownregulation activities are shown
on the flow cytometry plots. These values were calculated as the difference in levels of HLA-I mean fluorescence intensity between the p24-negative and the
p24-positive subsets divided by that of the p24-negative subset. (C)Quantitative assessment ofNefSF2-mediated downregulation activity towardHLA-A,HLA-B,
and HLA-C alleles. Symbols denote measurements obtained from experiments performed in quadruplicate. Horizontal bars denote median values and inter-
quartile ranges. The Mann-Whitney U test was used to calculate statistical significance.
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(IQR, 1.09 to 1.37), a value that differed significantly from the null
expectation of a ratio of 1.0 (Wilcoxon one-sample test, P 
0.001) (Fig. 2C).
Cells normally express two different allomorphs each of
HLA-A, HLA-B, and HLA-C (homozygotes excepted). As such, a
maximum of four different HLA-A and HLA-B allomorphs nor-
mally compete for Nef binding in infected cells (which differs
from our 721.221 cell system, where HLA alleles are expressed
singly). We therefore tested Nef-mediated downregulation of
HLA-A and HLA-B in the T1 human CD4 cell line that endoge-
nously expresses four different HLA-A and HLA-B alleles (see
Materials and Methods). Among them, HLA-A*02:01 (A02) and
HLA-B*51:01 (B51) are specifically detectable by MAbs for the
HLA-A2 serotype (clone BB7.2) and alleles belonging to theHLA-
Bw4 serotype group (clone TU109), respectively. The cytoplasmic
tails of A02 and A24 differ by a single amino acid (Fig. 1A),
whereas those of B51 and B35 are identical. Again, NefSF2 down-
regulated A02 more potently than B51 in T1 cells, with activities
(mean  SD) of 60.3%  1.6% and 51.6%  3.4%, respectively
(t test, P  0.0001). Moreover, all 46 patient-derived Nef clones
downregulated A02 (median, 58.3% [IQR, 54.5 to 63.2]) more
potently than B51 (median, 47.7% [IQR, 44.2 to 50.7]) (Mann-
Whitney test, P 0.0001) (see Fig. S2A in the supplemental ma-
terial). These values yielded amedian ratio of A02/B51 downregu-
lation in T1 cells by patient-derived Nef of 1.24 [IQR 1.18 to 1.29]
(see Fig. S2B),whichwas again significantly different from the null
expectation of a ratio of 1.0 (Wilcoxon one-sample test, P 
0.001).
HIV-1 Nef codons associated with differential HLA-A and
HLA-B downregulationWenext performed a pairwiseNef codon
function analysis to identify Nef amino acid residues associated
with A24 and B35 downregulation. At the predefined threshold of
a P value of 0.05 and a q value of 0.2, no Nef residues were
identified as being associated with A24 or B35 downregulation
ability (data not shown). However, when the analysis was per-
formed using the A24/B35 downregulation ratio as the functional
variable, Nef clones carrying Glu-158 exhibited significantly
higher A24/B35 downregulation ratios than those carrying an-
other amino acid at this site (P 0.00064, q 0.13). In contrast,
Nef clones carrying Tyr-202 exhibited significantly lower ratios
than those carrying another amino acid at this site (P 0.0017, q
 0.17) (Table 1). Using the T1 cell results as an independent
validation data set, we confirmed that Tyr-202 was significantly
associated with lower ratios (Mann-Whitney, P  0.04), while
Glu-158 showed a trend toward higher ratios, although this was
not statistically significant (P 0.11). These results suggested that
the amino acid residues at HIV-1 Nef codons 158 and 202 may
play a role in this protein’s differential recognition of HLA-A ver-
sus HLA-B allotypes.
Variation at Nef-202 modulates HLA-A and HLA-B down-
regulation. To examine the effects of amino acid residues at
codons 158 and 202 on selective downregulation of HLA-A and
HLA-B, we introduced various amino acid substitutions into
NefSF2 at these sites and analyzed the function of the mutant vi-
ruses. We introduced Ala, His, Lys, and Met substitutions at
codon 158 (wild-type Glu) and Ala, His, Leu, and Phe substitu-
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FIG 2 Downregulation of HLA-A, HLA-B, and HLA-C by primary Nef
clones. (A) 721.221 transfectants expressing A24, B35, or C04 were infected
with recombinant viruses carrying Nef clones isolated from 46 HIV-infected
patients. Three sets of representative flow cytometry plots, for the Nef clones
from patients CP66, CP84, and CP90, are shown. Nef-mediated HLA-I down-
regulation activities determined as described above are indicated in the plots.
(B) HLA-I downregulation activities by 46 patient-derived Nef clones in
721.221 transfectants expressing A24, B35, or C04 are shown. Bars and whis-
kers denote median results and interquartile ranges. Each plot represents the
mean results from 3 or 4 independent assays. Statistical analysis was done by
Mann-Whitney U test. (C) Ratios of levels of downregulation activity of A24
and B35 by 46 primary Nef isolates are shown. Bars and whiskers denote
median results and interquartile ranges. Dotted line represents the null expec-
tation of a ratio of 1.0. Statistical analysis was done by Wilcoxon one-sample
test.
TABLE 1 Nef amino acid residues associated with differential HLA-A/HLA-B downregulation ratios in 721.221 cells
Nef codona Amino acid
HLA-A/HLA-B downregulation
ratio for Nef cloneb: No. of subjects whose Nef clonec:
P value q valueWith residue Without residue Had residue Did not have residue
158 Glu 1.30 1.07 33 12 0.00064 0.13
202 Tyr 1.23 1.65 40 6 0.0017 0.17
a Nef codon numbers are based on the sequence of NefHXB2.
b Median HLA-A*24/HLA-B*35 downregulation activity ratio.
c The row total varies due to the gap in the aligned sequence.
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tions at codon 202 (wild-type Tyr). These substitutions included
naturally occurring residues (Ala, Lys, and Met at 158 and His,
Leu, and Phe at 202), as well as residues not observed in natural
Nef sequences (His at 158 and Ala at 202), as determined in our
cohort and in 1,470 publically available subtype B Nef sequences
in the Los Alamos HIV sequence database. The steady-state levels
of the wild-type Nef protein and the variants were comparable in
virus-producing cells (data not shown). We then tested the Nef
variants for A02 and B51 downregulation activity in T1 cells. No
mutation at codon 158 substantially influenced A02 or B51 down-
regulation activity or A02/B51 downregulation ratios (Fig. 3A). In
contrast, all mutations at codon 202, except Phe, significantly de-
creased Nef-mediated downregulation of both A02 and B51 in T1
cells compared to the downregulation activity of wild-type Tyr-
202 (Fig. 3B). Moreover, these mutations impaired B51 down-
regulation activity to a greater extent than they impaired A02
downregulation, resulting in corresponding A02/B51 downregu-
lation ratios that were also significantly higher (Fig. 3B). Specifi-
cally, the A02/B51 downregulation ratios for the Ala-, His-, and
Leu-202 mutations were 2.47  0.18, 1.72  0.21, and 2.55 
0.42, respectively, values that were 2.1-, 1.5- and 2.2-fold higher,
respectively, than that of wild-type NefSF2 (Tyr-202). Consistent
results were also obtained in 721.221 cells expressing A24 and B35
(see Fig. S3 in the supplemental material).
To further confirm the effect of Nef-202 on differential HLA-A
and HLA-B downregulation, we introduced a His-to-Tyr muta-
tion into patient CP66’s Nef clone at codon 202, thereby reverting
this clone to the wild-type sequence at this position. This particu-
lar patient clone was chosen because it exhibited substantially im-
paired HLA-B downregulation activity in T1 cells (A02/B51
downregulation ratio, 2.30 0.28), 721.221 cells (A24/B35 down-
regulation ratio, 1.86  0.04), and primary T cells (A02/B35
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FIG 3 Effects of defined Nef mutations on HLA-A and HLA-B downregulation activity. (A and B) NefSF2 and its variants at position 158 (A) and 202 (B) were
tested for downregulation activity towardA02 andB51 inT1 cells. The ratios of the results for A02 andB51were also determined.Data shown are themean results
 SD from 3 or 4 independent experiments. Statistical analysis was performed by analysis of variance (ANOVA)withmultiple comparisons versus the results for
the wild type (wt). n.s., not significant. (C) CP66-Nef clones encodingHis-202 and Tyr-202 were tested for downregulation activity in T1 cells (for A02 and B51),
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downregulation ratio, 2.16 0.25) (Fig. 3C). The introduction of
the His-to-Tyr reversion substantially increased A02 and B51
downregulation activity in T1 cells, A24 and B35 downregulation
activity in 721.221 cells, and A02 and B35 downregulation activity
in primary T cells (Fig. 3C). As the extent of functional rescue by
this reversion was more pronounced for HLA-B than for HLA-A
allotypes, the ratio of HLA-A/HLA-B downregulation activities of
CP66-Nef decreased to 1.29  0.06 in T1 cells, 1.23  0.01 in
721.221 cells, and 1.43  0.07 in primary T cells, values that are
comparable to the median for patient-derived Nef clones
(Fig. 2C). These data indicate that amino acid polymorphism at
Nef-202 alone canmodulate Nef’s ability to downregulate HLA-B
and, to a lesser extent, HLA-A allotypes.
HLA-I cytoplasmic motifs that modulate sensitivity to Nef-
mediated downregulation. Nef-mediated downregulation of cell
surface HLA-I molecules occurs through interaction between the
HLA cytoplasmic domain and Nef in conjunction with the clath-
rin adaptor protein complex 1 (AP1) (17, 36, 37). We sought to
identify HLA-I cytoplasmic motifs that determine sensitivity to
Nef-mediated downregulation. As shown by the sequences in
Fig. 1A, HLA-A and HLA-B alleles differ in their amino acid resi-
dues at codons 314 and 315, as well as in the presence (HLA-A) or
absence (HLA-B) of the C-terminal Cys-Lys-Val (CKV339–341)
motif. We therefore created a chimeric A02 molecule possessing
the cytoplasmic tail of B35 by introducing a GG314,315 mutation
into A02 and additionally deleting its C-terminal CKV339–341 mo-
tif; we designated this sequence A02GG,CKV. We then established
Jurkat T cells stably expressing A02 andA02GG,CKV, which exhib-
ited similar cell surface expression of these molecules upon stain-
ing with anti-HLA-A2 serotype antibody (mean fluorescence in-
tensities [MFI], 5,664  226 and 4,989  263, respectively)
(Fig. 4A). Infection of these cells with an HIV-1 NL43 strain en-
coding NefSF2 resulted in downregulation of A02 and A02GG,CKV
to similar levels (Fig. 4A and B). As expected, the introduction of
the His-202 mutation into NefSF2 impaired its ability to down-
regulate both A02 and A02GG,CKV, to a greater extent for the
latter. Specifically, the introduction of His-202 increased the A02/
A02GG,CKV downregulation ratio from 1.03 to 1.82, a 1.8-fold
increase (Fig. 4C). Complementary results were obtained with the
parental (His-202) and wild-type revertant (Tyr-202) CP66-Nef
sequences. Specifically, the CP66Tyr-202 revertantmutant exhib-
ited A02 downregulation activity comparable to that ofNefSF2 and
A02GG,CKV downregulation activity moderately lower than that
ofNefSF2 (Fig. 4A andB). In contrast, the parental CP66-Nef (His-
202) exhibited substantially impaired A02GG,CKV downregula-
tion activity. Overall, the Tyr-to-His substitution increased the
A02/A02GG,CKV downregulation ratio of CP66-Nef from 1.15 to
2.86, a 2.5-fold increase (Fig. 4C).
We further investigated potential interactions between Nef
codon 202 and the cytoplasmic tails of A02 and A02GG,CKV by
examining the existing crystal structure of theA02 cytoplasmic tail
and Nef in complex with the 1 subunit of AP1 (37). This crystal
structure exhibits an involvement of Tyr-202 of Nef in contacting
a portion of the 1 subunit of AP1 and forming a part of the
groove for HLA-I binding (Fig. 5A and B) (37). Although the
crystal structure did not include A02’s cytoplasmic tail in its en-
tirety (the last residue observed in the structure is Gly-331, which
lies seven residues upstream from the C-terminal CKV339–341 that
is present in A02 but absent in HLA-B alleles, since the remaining
region is disordered in three-dimensional space), the proximity of
Gly-331 to the main chain atoms of Nef Tyr-202 suggested that
CKV339–341 could also be located nearby. Indeed, modeling of a
7-amino-acid spacer following Gly-331 indicated that CKV339–341
could readily be positioned next to the side chain of Nef Tyr-202
for potential interaction (Fig. 5B). In contrast, the DR314,315 resi-
dues of HLA-A, present in the crystal structure, do not directly
contact any Nef residues (Fig. 5A). These data suggest that Nef
codon 202 and the C-terminal CKV339–341 motif that is present in
HLA-A but notHLA-B alleles, in conjunctionwith the1 subunit
of clathrin AP1,may form an interaction that enhances the down-
regulation of HLA-A over that of HLA-B.
Effects on T cell recognition. We postulated that Nef’s differ-
ential abilities to downregulate HLA-A and HLA-B molecules
would have consequences for T cell recognition of viral antigens
presented on the surface of HIV-infected cells (18–20, 35). To test
this hypothesis, we used a published reporter cell coculture assay
that features HLA-A*02:01-expressing target cells and HIV-1-
specific effector cells that transiently express a T-cell receptor
(TCR) specific for an HLA-A*02:01-restricted HIV-1 epitope in
Gag (FK10; Gag433–442 [FLGKIWPSYK]), human CD8- chain,
and an nuclear factor of activatedT cells (NFAT)-driven luciferase
construct (see Materials and Methods). When target cells are in-
fected with HIV, endogenously derived viral peptide antigens are
FIG 4 Effects of HLA-I cytoplasmic tail polymorphisms on Nef-mediated
HLA-A and HLA-B downregulation activity. (A) The amino acid sequence of
the cytoplasmic region of A02 was mutated to encode GG314,315 and a
C-terminal deletion mutant of the CKV339–341 motif, resulting in a cytoplas-
mic sequence identical to that of B35 (A02GG,CKV; see Fig. 1A). Jurkat trans-
fectants stably expressing A02 and A02GG,CKV were infected with recombi-
nant NL43 viruses encoding various Nef clones or remained uninfected. The
Nef clones tested were NefSF2 with Tyr-202 or His-202 and CP66-Nef with
Tyr-202 or His-202. Representative flow cytometry plots are shown, and the
levels of HLA downregulation activity are indicated in the plots. (B and C)
Quantitative assessment of the downregulation activities (B) and the activity
ratios (C) of A02 and A02GG,CKV are shown. The data shown are the mean
results SD from3 to 5 independent assays. Statistical analysis was performed
by paired t test. n.s., not significant.
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processed and presented in complex with A02 on their surface,
though the HIV Nef protein counteracts this by downregulating
HLA-I. When HIV-infected target cells are cocultured with A02-
FK10-specific reporter cells, TCR-dependent signaling can be
quantified based on luminescence. The ability of a given Nef se-
quence to downregulate HLA-I on the target cell thus correlates
inversely with the TCR-mediated luminescence signal in effector
cells.
We first undertook the following control experiments. Target
cells expressing either A02 or A02GG,CKV were pulsed with in-
creasing concentrations of FK10 peptide and cocultured with
A02-FK10-specific reporter cells, and the TCR-mediated signal
was quantified bymeasuring luminescence (Fig. 6A). As expected,
the luminescence intensity correlated positively with increasing
FK10 peptide concentrations in both A02 and A02GG,CKV target
cells. Moreover, the magnitudes of luminescence generated by
effector cells were comparable regardless of whether A02 or
A02GG,CKV target cells were used (Fig. 6A). This suggested that
A02 and A02GG,CKV target cells were equally sensitive to recogni-
tion by A02-FK10-specific TCR. Importantly, no response was
observed when parental target cells lacking HLA-A*02:01 were
pulsed with FK10 peptide, confirming the HLA- and antigen-
specific nature of the assay (Fig. 6A). Next, target cells were in-
fected with HIV-1 NL43-NefSF2 and NL43-Nef and incubated
with effector cells at various effector/target (E/T) ratios (Fig. 6B).
Effector cells cultured in the presence of A02 and A02GG,CKV
target cells infected with HIV-1 NL43-Nef generated much
greater luminescence signals than those cultured with control pa-
rental target cells lacking HLA-A*02:01. Furthermore, A02 and
A02GG,CKV target cells stimulated luminescence signals in effec-
tor cells with comparable magnitudes across all E/T ratios exam-
ined (Fig. 6B). In contrast, the effector cell responseswere dramat-
ically decreased when target cells were infected with NefSF2-
expressing HIV-1 (Fig. 6B). Together, the results of these control
experiments indicated that A02 and A02GG,CKV target cells were
similarly functional as target cells and that wild-type NefSF2 ex-
pression could substantially reduce T-cell recognition of HIV-
infected cells.
We then tested effector T-cell responses following coculture
with target cells infected with HIV-1 expressing NefSF2 or CP66-
Nef or their respective Nef-202 mutants. The effector T cell re-
sponses toward these Nef-positive (Nef), HIV-infected cells
were quantified by luminescence and normalized to the responses
generated against HIV-1-Nef-infected target cells. Consistent
with the results of the control experiments, the effector T cell
responses to A02 and A02GG,CKV target cells infected with HIV-1
NefSF2 (encoding Tyr-202) were comparable in magnitude
(Fig. 6C). In contrast, the responses to A02GG,CKV target cells
infected with HIV-1 NefSF2 encoding the His-202 mutation were
significantly higher than the responses to A02 target cells infected
with this virus (t test, P  0.0039) (Fig. 6C). Furthermore, while
the responses to A02 and A02GG,CKV target cells infected with the
FIG 5 Structural analysis of interaction between HLA-I cytoplasmic tail and Nef. (A) Interactions between A02 cytoplasmic domain, Nef, and 1 subunit of
adaptor protein 1 (AP1) are illustrated based on coordinates from the tripartite structure (PDB code 4EN2). The DR314,315 motif in the HLA-A cytoplasmic
domain, which corresponds to GG314,315 in the HLA-B cytoplasmic domain, is indicated. The C terminus of HLA-A was not observed in the structure; however,
the last observed C-terminal residue, G331, is located close to Nef Tyr-202. (B)Modeling suggests that the CKV339–341 motif may be located in the vicinity of the
side chain of Nef Tyr-202, allowing it to make a molecular contact. The dotted line depicts a potential path of the 7 amino acids, SDVSLTA, leading from G331
to the terminal CKV339–341 motif in HLA-A. MHC-I, major histocompatibility complex class I.
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HIV-1-CP66-Nef (Tyr-202) revertant virus were comparable in
magnitude and similar to those induced by NefSF2, we observed
significantly greater T cell responsiveness toward A02GG,CKV-
expressing target cells infected with HIV-1 encoding the parental
CP66-Nef (i.e., carrying the natural polymorphismHis-202) than
toward A02 target cells infected with the same virus (t test, P 
0.0001) (Fig. 6C). Moreover, the magnitude of responses against
the parental HIV-1-CP66-Nef virus was higher in both cells than
in cells infected with HIV-1 strains encoding NefSF2 or the CP66-
Nef (Tyr-202) revertant. Finally, the T cell responses as measured
in this assay andNef’sHLA-I downregulation activity asmeasured
by flow cytometry showed a significant inverse relationship (Pear-
son’s correlation coefficient, r  0.926, P  0.0008) (Fig. 6D).
Together, these results are consistentwith our observation that the
naturally occurring His-202 mutation attenuates Nef’s ability to
downregulate HLA-I, with a more pronounced impairment seen
for HLA-B (modeled herein by the A02GG,CKV construct) than
for HLA-A. Our results further suggest that inefficient removal of
HLA-B from the infected cell surface preferentially renders these
cellsmore detectable byHIV-specific,HLA-B-restricted effector T
cells.
DISCUSSION
In this study, we assessed the interplay between naturally occur-
ring host (HLA-I) and virus (HIV-1 Nef) polymorphisms. We
observed that HLA-B cytoplasmic tails displayed significantly de-
creased susceptibility to downregulation by primary HIV-1 Nef
clones compared to the susceptibility of HLA-A cytoplasmic tails.
On the host side, the relative resistance of HLA-B to downregula-
tion by patient-derived Nef clones appeared to be modulated by
the GG314,315 motif and/or the lack of the C-terminal CKV339–341
motif in the HLA-B cytoplasmic tail. On the viral side, HIV-1 Nef
codon 202 was responsible, at least in part, for differential down-
regulation ofHLA-A andHLA-B allotypes by this protein. Impor-
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FIG 6 Effects of differential levels of Nef sensitivity to HLA-A and HLA-B on antigen-specific TCR recognition. (A) Luciferase-reporter effector T cells
expressing an HLA-A*02-restricted HIV-1 Gag FK10-specific TCR were incubated with parental Jurkat target cells or Jurkat cells stably expressing A02 or
A02GG,CKV in the absence or presence of increasing concentrations of synthetic FK10 peptide at an E/T ratio of 1. T cell recognition is shownby the luminescence
intensity detected at 6 h. (B) The same effector cells were incubated with parental Jurkat target cells or those stably expressing A02 or A02GG,CKV that were
infected withHIV-1 encodingNefSF2 orNef at an E/T ratio of 1:0.3, 1:1, or 1:3. T cell recognition is shown as the luminescence intensity detected at 6 h. (C) The
same effector cells were incubated with parental Jurkat target cells or those stably expressing A02 or A02GG,CKV that were infected with HIV-1 encoding NefSF2
or CP66-Nef or their indicated residue 202 mutants. The relative T cell response was calculated as the luminescence intensity at 6 h, normalized to that of target
cells infected with NL43Nef (set to 100%). (A to C) Data shown for all panels represent themean results SD from 3 to 5 independent assays. Statistical analysis
was performedby paired t test. n.s., not significant.Over all experiments, the background luminescence intensity obtained by incubation of the effector cells alone
was 141.5 20.2, and the frequency of HIV-infected cells within the target cell population as determined by intracellular expression of the p24Gag protein was
45.7% 8.9%. (D) Correlation between relative T cell response and Nef’s HLA downregulation activity in both A02- and A02GG,CKV-expressing cells infected
with HIV-1 encoding NefSF2 or CP66-Nef or their respective Nef-202 amino acid variants. Data for the relative T cell response and Nef’s HLA downregulation
activity are derived from the results shown in Fig. 6C and 4B, respectively. Statistical analysis was performed by Pearson’s correlation analysis.
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tantly, the results from our TCR recognition assays indicated that
the differential susceptibilities of HLA-I molecules to downregu-
lation by patient-derived Nef clones are likely to modulate T cell
recognition of HIV-infected target cells presenting viral antigens
in complex with HLA-I on their surface.
While it has long been known that HLA-B-restricted T cell
responses exert a dominant influence on HIV-1 immune control
(38, 39), it was only recently that the relative resistance of HLA-B
to Nef-mediated downregulation was put forward as a possible
underlying mechanism (23). The present study extends the previ-
ous work, which was performed using laboratory-adapted HIV-1
reference strains, by demonstrating that the majority of naturally
occurring Nef sequences also downregulate HLA-A to a greater
degree than HLA-B. Our results thus identify differential levels of
susceptibility to HLA-A and HLA-B as a fundamental property of
HIV-1 subtype B Nef sequences.
The introduction of various amino acid substitutions at Nef
codon 202 (wild-type Tyr) substantially affected the protein’s
ability to downregulate HLA-I, with greater impairment of
HLA-B downregulation than of HLA-A downregulation. In par-
ticular, the uncommon natural variants Leu and His and the un-
natural variant Ala displayed this phenotype, while the common
natural variant Phe conferred onlymodest effects compared to the
activity of Nef with the wild-type Tyr. This provides a possible
explanation for the relative frequency of these residues in natural
subtype B HIV-1 Nef sequences. Of interest, the Nef Phe-202
polymorphism has been identified as being associated with host
expression of HLA-A*30:01 and HLA-B*15:01 (40), suggesting
that it may arise under immune selection pressure by these alleles
in vivo; however, we were unable to confirm this experimentally
due to limited availability of peripheral blood mononuclear cells
(PBMC) from this cohort. Also of interest, while Tyr and Phe are
frequently observed at Nef codon 202 in all HIV-1 group M sub-
types, the consensus at this residue in HIV-1 group O is Leu (Los
Alamos HIV-1 sequence database). Given our observation that
the Leu-202 substitution in NefSF2 substantially increased the
HLA-A/HLA-B downregulation ratio (Fig. 3B), it would be in-
triguing to investigate downregulation of HLA-I molecules by
naturally occurring HIV-1 group O Nef sequences.
Some limitations of this study merit mentioning. Although we
investigated 46 patient-derived HIV-1 subtype B Nef clones, this
panel of sequences did not capture the entirety ofHIV-1 subtype B
Nef genetic diversity. Nevertheless, this relatively small subset of
patient isolates exhibited a substantial dynamic range of HLA-A
and HLA-B downregulation function. Importantly, the majority
of Nef clones were less able to downregulate HLA-B than HLA-
A—an observation that remained true for all cell lines and pri-
mary T lymphocytes, as well as all individual HLA alleles and
cytoplasmic variants tested. As our goal was to investigate Nef-
mediated HLA-A and HLA-B downregulation on the surface of
HIV-infected cells, we employed recombinant virus approaches
(as opposed to transient-transfection systems, which are limited
by Nef overexpression and potential cytotoxicity during plasmid
delivery). Nevertheless, recombinant approaches are inherently
limited by potential incompatibilities between the insert and the
backbone (though all of the recombinant viruses used were repli-
cation competent and demonstrated Nef polyfunctionality in var-
ious cell lines and primary T cells, as demonstrated in a previous
published study of these clones [41]). The crystal structure of a
ternary complex formed by Nef, the HLA-A02 cytoplasmic tail,
and the cargo-bonding 1 subunit of AP1 was recently solved
(37), yielding new insight into the molecular basis of Nef-
mediated HLA-I downregulation function. However, due to the
disordered nature of the C-terminal end of the HLA-A02 cyto-
plasmic tail, this region was not included in the structure (37),
rendering it impossible to directly investigate interactions be-
tween this region (notably, the C-terminal CKV339–341 motif) and
Nef-202. Nevertheless, modeling of a 7-amino-acid spacer follow-
ing Gly-331, the final residue of the HLA-A02 cytoplasmic tail
observed in the structure, indicated that the CKV339–341 motif
could readily be positioned next to the side chain of Nef Tyr-202,
supporting a possible interaction.
Despite these limitations, our study extends the current under-
standing of Nef-mediated HLA-I downregulation function by
demonstrating that, on average, subtype B Nef sequences from
untreated, chronically HIV-infected patients downregulate
HLA-A ~1.25-fold more efficiently than HLA-B. Moreover, these
effects appear to bemodulated, at least in part, by polymorphisms
at Nef residue 202, as well as those located within the HLA-I cyto-
plasmic domain. Importantly, the differential levels of Nef-
mediated HLA-A and HLA-B downregulation on HIV-infected
cells modulate their subsequent recognition by HIV-specific T
cells. Together, these results identify a new motif in HIV-1 Nef
that differentially alters its ability to counteractHLA-A- andHLA-
B-restricted CTL responses. Further studies will be necessary to
determine whether Nef polymorphisms at residue 202 are associ-
ated with variations in immune-mediated control of infection or
viral pathogenesis.
MATERIALS AND METHODS
Patient-derived Nef clones and recombinant virus preparation. The re-
combinant viruses expressing patient-derived Nef clones in an HIV-1
NL43 proviral backbone were generated as part of previously published
studies (28, 30, 41). Briefly, Nef sequences were isolated from plasma viral
RNA of 46 individuals chronically infected with HIV-1 subtype B, re-
cruited in the Boston area, who were untreated at the time of sample
collection and had a median plasma viral load of 80,500 (IQR, 25,121 to
221,250) RNA copies/ml and a median CD4 count of 292.5 (IQR, 72.5 to
440) cells/mm3, as described previously (30, 42, 43). This study was ap-
proved by the Institutional Review Boards at all relevant institutions, and
all participants provided written informed consent. The GenBank acces-
sion numbers for clonal nef sequences used in this study are JX440926 to
JX440971 (41). To facilitate a consistent codon numbering scheme (based
on the sequence of the NefHXB2 reference strain), all clonal Nef sequences
were pairwise aligned to that of NefHXB2 and insertions stripped out.
Patient-derived nef clones isolated as described above were transferred
into plasmid pNL43 and confirmed by sequencing as described previously
(41). In addition, specific mutations (i.e., at Nef codons at 158 and 202)
were introduced into the nef clone of strain SF2 using conventional over-
lapping PCR (33, 35), and the entire nef sequence was reconfirmed after
subcloning into pNL43. The resultant DNA (5 g), along with a plasmid
encoding vesicular stomatitis virus envelope glycoprotein (VSV-g) (1g),
was transfected into 106 293T cells, and the virus-containing culture su-
pernatants were harvested 48 h later. Recombinant viruses harboring nef
fromHIV-1 subtype B reference strain SF2 (NefSF2) or lacking nef (Nef)
were used as positive and negative controls, respectively, as previously
described (30, 35).
Cells and antibodies for HLA analysis. Nef-mediated downregula-
tion of cell surface expression of HLA-I molecules was assessed using the
following four different cell systems: (i) 721.221, an HLA-A, -B, and -C-
null human lymphoblastoid cell line, which was transfected to express a
single HLA-I allele; (ii) T1, a human CD4 monocytic cell line that ex-
presses 6 different autologous HLA-I alleles (2 alleles each of HLA-A, -B,
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and -C); (iii) human primary T lymphocytes isolated from HIV-negative
donors expressing autologous HLA-A*02 and HLA-Bw6 serotype alleles;
and (iv) Jurkat, a human CD4 T cell line that was stably transfected with
genes encoding HLA-A*02:01 or its cytoplasmic tail mutant. For the first
system, we used theHLA-A, -B, and -C-null 721.221 cell line (44) that had
been engineered to stably express a single HLA class I allele encoding
HLA-A*02:01, HLA-A*24:02, HLA-A*33:03, HLA-B*35:01, HLA-B*57:
01, or HLA-C*04:01. These transfectants were kindly provided by M.
Takiguchi, Kumamoto University, Japan, or T. Yamamoto, Vaccine Re-
search Center, NIH, United States. HLA-I expression for each of the
721.221 lines was validated by HLA genotyping methods as described
previously (45), and HLA-I cell surface expression was confirmed by
staining with a pan-HLA-I-specific antibody (clone w6/32; BioLegend
Co.), followed by flow cytometry. For the second system, the human
CD4monocytic cell line T1 was used. The HLA-I genotyping results for
T1 cells were A*02:01, A*31:01, B*40:01, B*51:01, C*01:02, and C*03:04.
In the case of T1 cells, the cell surface expression of the specific HLA-I
alleles HLA-A*02:01 and HLA-B*51:01 was evaluated using an HLA-A2
serotype-specific MAb (clone BB7.2; BioLegend) and an HLA-Bw4
serotype-specific MAb (clone TU109; kindly provided by M. Takiguchi),
respectively. For the third system, primary T lymphocytes were isolated
from PBMC of HIV-negative donors, followed by activation with phyto-
hemagglutinin for 5 days. For the fourth system, the human CD4 Jurkat
T cell line was used. Human cDNA encoding HLA-A*02:01 was cloned
from PBMC of a healthy HLA-A*02:01-positive volunteer into plasmid
pcDNA3.1. Mutations (DR314,315 to GG314,315 and deletion of CKV339–
341) were introduced into the cytoplasmic tail region of HLA-A*02:01,
giving rise to HLA-A02GG,CKV, in which the cytoplasmic tail region is
equivalent to that of HLA-B*35:01. In all cases, the levels of cell surface
expression of HLA-A02 and its cytoplasmic tail mutant were evaluated by
an HLA-A2 serotype-specific MAb as described above.
HLA-I downregulation assay. The 721.221, Jurkat, T1, and primary T
cells were infected with the VSV-g-pseudotyped recombinant HIV-1 and
harvested 48 h later for staining with a pan-HLA-I-specific antibody
(clone w6/32; BioLegend Co.) or the serotype-specific MAbs, followed by
7-amino-actinomycin D (BioLegend Co) staining and intracellular
p24Gag staining with anti-p24 Gag-fluorescein isothiocyanate MAb
(KC57; Beckman Coulter) as previously described (30). Live cells (nega-
tive for 7-amino-actinomycin D) were gated, and HLA-I expression in
p24 and p24-negative subsets was analyzed by flow cytometry (FAC-
SCanto II or FACSVerse; BD Biosciences). For calculation of the HLA-I
downregulation activity by Nef, the following formula was used (where
MFI is mean fluorescence intensity): (MFI of HLA-I in p24-negative sub-
setMFIofHLA-I in p24-positive subset)/MFI ofHLA-I in p24-negative
subset.
T cell recognition assay. The effects of Nef-mediated HLA-I down-
regulation on T cell recognition were analyzed using a T cell receptor
(TCR)-based reporter cell assay as previously described (46, 47). Briefly,
the effector cells were prepared by electroporation of Jurkat cells with
expression plasmids encoding TCR- and - chains specific for the HLA-
A*02:01-restricted HIV-1 Gag FK10 epitope (Gag433–442 [FLGKI-
WPSYK]), human CD8- chain (InvivoGen), and NFAT-luciferase re-
porter (Affymetrix). The resultant cells were incubated for 24 h, followed
by separation of the CD8-expressing fraction by magnetic bead sorting
(Miltenyi). Target cells were prepared by infection of parental Jurkat cells
(lacking A02) or Jurkat cells transfected with A02 or A02GG,CKV with
recombinant HIV-1 encoding nef alleles of interest. For control experi-
ments, uninfected target cells were pulsed with the synthetic FK10 pep-
tide. Effector cells (5 104 cells) were coculturedwith target cells (5 104
cells, unless otherwise specifically indicated) for 6 h and then harvested for
the luciferase assay (Steady-Glo luciferin kit; Promega). Luminescence
was measured by using a plate reader (CentroXS3; Berthhold Technolo-
gies) with the following conditions: 3,000ms integration and 100ms settle
time.
Western blotting. HEK-293T cells were transfected with proviral
DNAs encoding NefSF2 or mutants for preparation of cell lysates as de-
scribed previously (30, 31). Briefly, lysates were prepared in duplicate,
subjected to SDS-PAGE, transferred to nitrocellulose membranes, and
stained with rabbit anti-Nef polyclonal antiserum (NIH AIDS Research
and Reference Reagent Program), followed by secondary enhanced
chemiluminescence rabbit IgG (horseradish peroxidase-linked whole an-
tibody; GE Healthcare Life Sciences), as reported previously (30). Band
intensities were quantified using the Amersham Imager 600 (GE Health-
care Life Sciences).
Statistical analysis. Statistical analyses were performed using Graph
PadPrism6.0. ForNef codon function analyses, theMann-WhitneyU test
was used to identify amino acids associated with differential abilities to
downregulate HLA-A and HLA-B (expressed as HLA-A/HLA-B down-
regulation ratios). Multiple comparisons were addressed using q values,
the P value analogue of the false discovery rate (FDR), which denotes the
expected proportion of false positives among results deemed significant at
a given P value threshold (48). For example, at a q value of0.2, we expect
20% of identified associations to represent false positives. In the present
study, statistical significance was defined as a P value of 0.05 (for uni-
variate analyses) or a P value of0.05 and a q value of0.2 (for analyses
correcting for multiple hypothesis testing).
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